Review
Donor-Derived Cell-Free DNA to Diagnose Graft Rejection Post-Transplant: Past, Present and Future

Naveen Kumar 1,2,3, Rashmi Rana 2,* , Devender Singh Rana 3, Anurag Gupta 3 and Mohinder Pal Sachdeva 1

Citation: Kumar, N.; Rana, R.; Rana, D.S.; Gupta, A.; Sachdeva, M.P. Donor-Derived Cell-Free DNA to Diagnose Graft Rejection Post-Transplant: Past, Present and Future. Transplantology 2021, 2, 348–361. https://doi.org/10.3390/transplantology2030034

Abstract: Donor-derived cell-free DNA (dd-cfDNA) is a non-invasive biomarker that is more sensitive and specific towards diagnosing any graft injury or rejection. Due to its applicability over all transplanted organs irrespective of age, sex, race, ethnicity, and the non-requirement of a donor sample, it emerges as a new gold standard for graft health and rejection monitoring. Published research articles describing the role and efficiency of dd-cfDNA were identified and scrutinized to acquire a brief understanding of the history, evolution, emergence, role, efficiency, and applicability of dd-cfDNA in the field of transplantation. The dd-cfDNA can be quantified using quantitative PCR, next-generation sequencing, and droplet digital PCR, and there is a commendatory outcome in terms of diagnosing graft injury and monitoring graft health. The increased levels of dd-cfDNA can diagnose the rejection prior to any other presently used biochemistry or immunological assay methods. Biopsies are performed when these tests show any signs of injury and/or rejection. Therefore, by the time these tests predict and show any unusual or improper activity of the graft, the graft is already damaged by almost 50%. This review elucidates the evolution, physiology, techniques, limitations, and prospects of dd-cfDNA as a biomarker for post-transplant graft damage and rejection.

Keywords: dd-cfDNA; non-invasive biomarker; graft rejection; graft health

1. Introduction

Solid organ transplant (SOT) is an effective therapy for end-stage diseases and organ failures, which is a lifesaving, transformational and restorative procedure for improving the quality and longevity of life. SOT relies on the effective surveillance of graft which includes serial laboratory testing and biopsies.

163,138 transplants were performed in 2019 worldwide, including 105,231 kidney transplants, 39,007 liver transplants, 9140 heart transplants, 7144 lung transplants, 2479 pancreas transplants, and 137 small bowel transplants [1]. Every transplant needs precise and frequent monitoring. Biopsies cannot be performed frequently and are performed when any clinical symptoms are triggered [2,3].

The immune system acts on all foreign particles that enter the body and produces antibodies in response. Similarly, when an organ is transplanted, the immune system recognizes it and acts against it, consequently destroying the perceived foreign cells in the form of the transplanted organ [4,5]. Due to the huge gap between the need and availability of organs, one cannot risk an organ failure after a transplant, owing merely to the immune response. To overcome this several measures are taken at each step, right from the beginning where the best suitable match for the organ is searched for, succeeded by the advanced medications and immunotherapy given to the recipients in order to suppress the immune response, until the enhanced post-transplant patient care.
Post-transplant recipients are kept under surveillance and strict regimes to avoid any complications that may lead to either damage or rejection of the transplanted organ [6,7]. Around 7% of renal transplants fail after a year, 17% fail after 3 years, and 46% fail after 10 years [8]. Among heart transplants, about 10% of the transplants fail in one year and 30% in 5 years [9–11]. Similarly, among liver transplant recipients around 20% of failures are reported in 1 year and 30% of failures in 5 years [12,13], thereby making graft rejection a pertinent obstacle in transplantation.

Large-scale screening processes undertaken in the 2000s in Australia, Norway, and the United States revealed that more than 10% of adults had markers for chronic kidney disease (CKD). The prevalence of CKD is in 9.1% of the global population [14]. More than 500,000 people in the United States live with ESRD [15]. Heart failure is a global health issue, with a prevalence of over 23 million cases worldwide [16]. It is predicted that by the end of 2030; 3 million additional patients will be added to these figures [17]. One out of every nine deaths in America is caused by heart failure [18]. There were 112 million reported cases of prevalent compensated cirrhosis and 10.2 million cases of decompensated cirrhosis worldwide, in 2017 [19]. The figures are indicative of the rising cases of organ failures and thereby hint at a scenario of unaffordable graft rejections.

After transplantation patients are required to undergo biopsy in order to diagnose graft dysfunction or rejection. Therefore, there is a pressing need to explore potential biomarkers which could be used as early detection mechanisms for monitoring graft health, graft damage, and rejection. The currently available non-invasive methods to detect damage and rejection are insufficient and donor-derived cell-free DNA (dd-cfDNA) seems to be very promising as a non-invasive biomarker. This review was conducted to explore the evolution of dd-cfDNA, its utility and future perspectives as a potential biomarker, as it summarizes the origin, current advancements and efficacy of dd-cfDNA in diagnosing graft injury and rejection. We believe that this review will inspire researchers to carry out further research in the field and add to the existing body of knowledge.

2. Materials and Methods

2.1. Search Strategy

This review was conducted in accordance with Preferred Reporting Items for Systematic and Meta-Analysis (PRISMA) guidelines. A literature review was performed using PubMed and Web of Science for finding relevant studies published as of 31 January 2021, without any language restrictions. The full search strategy is depicted in Figure 1.

The search terms included “donor derived cell free DNA”, “dd-cfDNA” and “graft cell free DNA”. Relevant literature reviews and references of included studies were also searched to identify other relevant analyses.

2.2. Study Selection

We included original articles published up to 31 January 2021 that investigated the role and utility of donor-derived cell-free DNA in diagnosing or monitoring graft rejection or graft health. We considered all types of study-randomized control trials, non-randomized prospective cohorts, retrospective cohorts, case reports, or case series. Inclusion and exclusion criteria were formulated to ensure comprehensive searching and screening for published articles relevant to diagnosing rejection/health of any solid organ transplant. Studies were excluded if they met any of the following criteria: markers other than donor-derived cell-free DNA, transplants other than solid organs, non-English publication, unavailable full texts, or non-peer reviewed texts. The published study reporting the utility of dd-cfDNA in graft health monitoring and rejection diagnosis were included.

Titles and abstracts were independently reviewed by two authors (N.K. and R.R.). After screening, the full text of the articles was reviewed by three authors (N.K., R.R. and A.G.). The two screeners discussed items in which there was a disagreement and if a consensus could not be reached, the third author’s adjudication was sought (M.P.S.).
3. Evolution of Analytical Approaches and Techniques to Diagnose Graft Rejection Using dd-cfDNA

Thomas Earl Starzl, an American physician who performed the first liver transplant in humans, provided the first ever well-defined evidence for the presence of donor DNA in the bloodstream of a recipient, which was ascertained by karyotyping studies in female recipients of liver transplants who obtained a graft from cadaveric male donors and proved that the organ genome becomes chimera in transplanted patients [20]. ‘Graft chimerism might be a generic feature of all accepted graft’ was theorized after the evidence of chimeras observed in intestine, kidney, lung, heart, and liver transplants [21–25].

Evidence of the presence of Y chromosomes in the recipient’s urine and plasma of sex-mismatched donor-recipient pairs revealed that increased level of dd-cfDNA could be an indicator for rejection and acceptance of the graft [26–30]. A major drawback of this approach was that it was pertinent only to a female recipient who obtained an organ from a male donor. Therefore, this limited the number of transplant cases and reduced its applicability in a minority of cases. Despite its limitations, it led to the genesis of the idea of microchimerism, which is the presence of small amounts of cells originated from another individual having different genetic information from the host.

This microchimerism directed the researchers and scientists to identify and quantify the donor DNA in the recipient by discovering an assay which could be applicable to all the recipients irrespective of age, sex and the type of organ transplanted. Hence a...
universal, sex-independent assay was introduced which required the genotyping of both donor and recipient. Single nucleotide polymorphisms (SNP), which are homozygous and can distinguish donor DNA from recipient DNA, were selected for further analysis and quantification. This method relied upon knowledge of donor and recipient genotypes, which required time, a donor sample, and was costly. Shotgun sequencing was not possible in a regular hospital setting because of its high turnaround time and because genotyping both the donor and recipient was time- and effort-constraining.

Thus, the proposed technique takes a leap over the need of genotyping both the donor and recipient as it proposes the uses of the assay of preselected SNPs which are applicable to all donor recipients’ pairs, irrespective of age, sex, ethnicity, and organs. An SNP should be homozygous in both donor and recipient, and should differ between the two. To select such SNPs, we can either genotype both donors and recipients and select the homozygous different SNPs which identify donor DNA and can be further quantified. The other approach is preselecting a panel of informative SNPs from the public genomic databases like HapMap, 1000 Genomes, and Indi Genomes. This informative panel of preselected SNPs contains SNPs with high minor allele frequency (MAF) of 0.4–0.5. The SNPs selected should not be located within or directly adjacent to an annotated repetitive element. Considering the Hardy–Weinberg equilibrium an SNP with an MAF of 0.4–0.5 has a nearly equal distribution of both alleles in a population and an 11.5 to 12.5% chance of containing a homozygous genotype in two individuals: the recipient and the donor. It has approximately a 23–25% chance of being homozygous for each allele in an individual. Hence, an informative panel of a set of 30–35 SNPs is enough to identify 3 SNPs for each donor–recipient pair to assess the damage and rejection in the recipient [31]. However, if SNPs were selected randomly without the required MAF, then approximately 3000 SNPs would be available to test for homozygosity between the donor and the recipient [32].

Presently, there are two simultaneous techniques for using dd-cfDNA; as biomarkers, based on the measurement of the number of donor molecules by next-generation sequencing or the digital PCR method. The next-generation sequencing method uses 266 SNPs panel in comparison to 41 SNPs used by the droplet digital method by Beck et al. [32,33]. Both of these methods lead to the same results [34].

An individual genome carries approximately 4–5 million SNPs and there are more than 100 million SNPs across the populations globally. Only 0.1–1% of DNA differ between any two individuals, depending on the degree of relatedness [35]. An SNP may be unique to an individual or a population. In forensic science, SNPs are used to establish identities. Similarly, the SNPs are used in transplantation for identifying different DNA circulating in the plasma of the recipient.

Genomic biomarkers are more complex than standard chemistry diagnostics. Hence, they require advanced methods, workflows, and analytical approaches. The assays detecting dd-cfDNA differ in technology and methods. Therefore, each of the assays requires clinical validation before introducing it in a clinical setting. The chronology of the advancement and use of different methods and techniques for identifying and quantifying the donor-derived cell-free DNA during the last two decades are elucidated in Table 1.
Table 1. A timeline comparison of methods and techniques to assess dd-cfDNA to diagnose rejection.

| Name            | Organ(s)       | Sample Type     | dd-cfDNA Method                                      | Technique                  | Donor Sample Required |
|-----------------|----------------|-----------------|------------------------------------------------------|----------------------------|-----------------------|
| Zhang 1999 [26] | Kidney         | Urine           | Sex mismatch (SRY gene)                              | Real-time quantitative PCR | No                    |
| Moreira 2009 [27] | Kidney        | Plasma, Urine   | Hemoglobin, beta (HBB) gene & TSPY1 gene             | Quantitative PCR           | Yes                   |
| Synder 2011 [30] | Heart          | Plasma          | Sex mismatch (Chr Y) & shotgun sequencing            | Digital PCR                | Yes                   |
| Sigdel 2013 [29] | Kidney         | Urine           | Sex mismatch (SRY gene)                              | Digital PCR                | No                    |
| Beck 2013 [32]  | Heart, Kidney, Liver | Plasma        | Informative SNP panel                               | Droplet digital PCR        | No                    |
| Vlaminck 2014 [36] | Heart         | Plasma          | Whole-genome arrays                                 | Quantitative PCR           | Yes                   |
| Macher 2014 [28] | Liver          | Plasma          | SRY & beta-globin gene                               | Real time quantitative PCR  | No                    |
| Vlaminck 2015 [37] | Lungs         | Plasma          | Whole-genome arrays                                 | Quantitative PCR           | Yes                   |
| Beck 2015 [38]  | Heart, Kidney  | Plasma          | Informative SNP panel                               | Droplet digital PCR        | No                    |
| Burnham 2016 [39] | Lungs          | Plasma          | SNP sequencing with mitochondrial reference sequences| Quantitative PCR           | Yes                   |
| Macher 2016 [40] | Liver          | Plasma          | RH-negative recipient & RH-positive donor pair       | Real time PCR              | Yes                   |
| Grskovic 2016 [33] | Heart, Kidney | Plasma          | Informative SNP panel                               | Next-generation sequencing  | No                    |
| Schutz 2016 [41] | Liver          | Plasma          | Informative SNP panel                               | Droplet digital PCR        | No                    |
| Zou 2017 [42]   | Lung           | Plasma          | HLA specific primers and probes                      | Droplet digital PCR        | No                    |
| Bromberg 2017 [43] | Kidney        | Plasma          | Informative SNP panel                               | Next-generation sequencing  | No                    |
| Goh 2017 [44]   | Liver          | Plasma          | Deletion/Insertion Polymorphism (DIP) panel          | Droplet digital PCR        | Yes                   |
| Schutz 2017 [3]  | Liver          | Plasma          | Informative SNP panel                               | Droplet digital PCR        | No                    |
| Bloom 2017 [45] | Kidney         | Plasma          | Informative SNP panel                               | Next-generation sequencing  | No                    |
| Tanaka 2018 [46] | Lung           | Plasma          | SNP genotyping & informative SNP panel              | Droplet digital PCR        | Yes                   |
| Jordan 2018 [47] | Kidney         | Plasma          | Informative SNP panel                               | Next-generation sequencing  | No                    |
| Weir 2018 [34]  | Kidney         | Plasma          | Informative SNP panel                               | Next-generation sequencing  | No                    |
| Beck 2018 [2]   | Heart          | Plasma          | Informative SNP panel                               | Droplet digital PCR        | No                    |
| Gielis 2018 [48] | Kidney         | Plasma          | Deletion/Insertion Polymorphism (DIP) panel          | Next-generation sequencing  | Yes                   |
| Goh 2019 [49]   | Liver          | Plasma          | Deletion/Insertion Polymorphism (DIP) panel          | Droplet digital PCR        | Yes                   |
| Khush 2019 [50] | Heart          | Plasma          | Informative SNP panel                               | Next-generation sequencing  | No                    |
| Altug 2019 [51] | Kidney         | Plasma          | Bi-allelic SNP on Chr-2,13,18,21                    | Massively multiplexed PCR  | No                    |
| Sigdel 2019 [52] | Kidney         | Plasma          | SNP-based assay & LabChip NGS 5k                    | Massively multiplexed PCR-next-generation sequencing | No                    |
| Oellerich 2019 [53] | Kidney       | Plasma          | Informative SNP panel                               | Droplet digital PCR        | No                    |
Table 1. Cont.

| Name            | Organ(s) | Sample Type | dd-cfDNA Method          | Technique                  | Donor Sample Required |
|-----------------|----------|-------------|--------------------------|----------------------------|-----------------------|
| Sayah 2020 [54] | Lung     | Plasma      | Informative SNP panel    | Next-generation sequencing | No                    |
| Potter 2020 [55]| Kidney   | Plasma      | Informative SNP panel    | Next-generation sequencing | No                    |
| Schutz 2020 [56]| Kidney   | Plasma      | Informative SNP panel    | Droplet digital PCR        | No                    |
| Shen 2020 [57]  | Kidney   | Plasma      | Informative SNP panel    | Next-generation sequencing | No                    |
| Puliyanda 2020  | Lung     | Plasma      | Informative SNP panel    | Next-generation sequencing | No                    |
| Stites 2020 [59]| Kidney   | Plasma      | Informative SNP panel    | Next-generation sequencing | No                    |
| Khush 2021 [60] | Lung     | Plasma      | Informative SNP panel    | Next-generation sequencing | No                    |

Abbreviations: Chr, chromosome; HLA, human leukocyte antigen; PCR, polymerase chain reaction; RH, Rhesus factor; SNP, Single nucleotide polymorphism; SRY, sex-determining region Y.

4. The dd-cfDNA as a Potential Biomarker

Donor-derived cell-free DNA (dd-cfDNA), also referred to as graft cell-free DNA (GcfDNA) or donor-specific DNA (ds-DNA), is a biomarker which works on the principle/fact that an organ transplant is not just a transplant of an organ but also the transplant of a genome. The biological rationale behind the utility of dd-cfDNA is that the immune system is activated upon recognition of the transplanted organ and produces antibodies in response. The antibodies attack the transplanted organ which leads to apoptosis or cell necrosis. The ruptured or dead cells release their contents into the recipient’s blood plasma and thereafter, the recipient carries the DNA of the donor, which reflects in its name, ‘donor-derived cell-free DNA’. This is cell-free, circulating and donor DNA.

Donor-derived cell-free DNA is found in all recipients irrespective of whether the recipient shows rejection or not, although the number of cells may vary from individual to individual (Figure 2) [20]. Furthermore, even after using different methods for the identification and quantification of dd-cfDNA, in stable patients similar median values are obtained [61].

Large numbers of donor cells are present in individuals experiencing graft damage and/or rejection due to the breakdown of cells.

The clearance of dd-cfDNA from an individual’s body is similar to that of cell-free DNA, though it is still being studied and requires further research.

The half-life of cell-free DNA in the bloodstream is between 16 min to 2.5 h [62,63]. Cell-free DNA can enter the liver or spleen and be degraded by the macrophages that are located inside by the action of the DNase I enzyme [64]. Cell-free DNA can also be excreted through urine.

The pertinent questions that open the purview of the discussion concerning “whether dd-cfDNA is cleared out from the body through urine?” and “Is increased level of dd-cfDNA associated with impaired kidney function rather than actual graft damage?” Some insight can be gained even though it is unknown which mechanism is involved in clearing out the cell-free DNA from the blood plasma of the recipient, but a study on foetal DNA cleared out from maternal blood circulation showed that only 0.2 to 19% of the total foetal DNA is cleared out by the kidney, stating that renal excretion is not a major route when it comes to the clearance of non-host (foetal) DNA [65]. Donor DNA is always present in the plasma of the recipient in varying quantities.
The recipient also carries its own cell-free DNA. So, the quantification of donor DNA will help to monitor the graft health, damage and rejection. For the quantification of dd-cfDNA, SNPs are best-suited as they can differentiate dd-cfDNA from the recipient cf-DNA. The polymorphism between the donor and the recipient must be identified. Therefore, for diagnosing graft damage and rejection, the panel of SNP's used must be able to differentiate between individuals.

Currently used methods for monitoring the organ health and diagnosing the rejection are based on signs and symptoms of patient, biochemistry tests, immunological assays, and biopsies. Serum creatinine (sCr) is increased if there is a significant reduction in the glomerular filtration rate (GFR), and about 50% of the kidney function is lost before a rise in sCr is detected, hence making it a late marker for acute rejection [66].

Biopsy being a ‘gold standard’ for assessing the health and rejection of an organ is an invasive technique and has its own set of limitations, including the turnaround time, expense, inconvenient process, chances of sampling error, inter-observer variability and poor recommendation for serial testing. Biopsies are performed on suspicion of damage or graft rejection and almost 50% or more of the organ is typically injured before it is recommended for biopsy [66–68]. Due to this, asymptomatic graft injuries remain undiagnosed. However, endomyocardial biopsy is also not a true gold standard for diagnosing acute rejection [50].

Approximately 25% of biopsies yield an inadequate specimen and this risk can become larger with a smaller needle size. Because of the modern immunosuppression, many units no longer perform routine biopsies [69]. In a study by Bloom et al. It was found that only 27% of the clinically indicated biopsies in kidney transplant patients revealed active rejection, where the biopsies were performed after observing an elevation in the sCr over
baseline [36]. In another study by Yang et al., 43% of the clinically indicated biopsies were found quiescent and 65% of the protocol biopsies were tagged as unnecessary invasive procedures [4].

5. Monitoring of Organ Damage and Rejection through dd-cfDNA

The monitoring of dd-cfDNA is based on the number of donor DNA copies circulating in the plasma of recipients. The levels of dd-cfDNA in stable patients are significantly less when compared to rejection cases. High levels of dd-cfDNA are associated with the rejection cases in liver, kidney, heart, lung transplant recipients [27–30,32–34,36–40,42–44,47–50,52,53,70–72]. The dd-cfDNA levels begin to rise from weeks to months before acute rejection is diagnosed by the currently used methods. These increased levels represent early graft damage or injury [3,30,36]. The dd-cfDNA is highly efficient in detecting injury and rejection caused due to antibody mediated rejection (ABMR). But, when it comes to T-cell mediated rejection (TCMR), some studies have also shown that TCMR is associated with elevation in dd-cfDNA. TCMR type IB, type IIA, type IA and borderline rejection shows a high percentage of dd-cfDNA, but according to a study by Sigdel et al., it is averred that the dd-cfDNA method is unable to detect TCMR [45,52,53,59]. Further studies are needed to assess the role of dd-cfDNA in detecting TCMR rejection.

The elevation of dd-cfDNA is not always linked to rejection but also points out the degree of graft injury and infection. Immediately post-transplant the level of dd-cfDNA is increased but decreases after a couple of days of kidney transplant, liver transplant, lung transplant and heart transplant, which is also reflective of ischemia or reperfusion injuries in the transplanted organs (Figure 3) [26,32,39,41,47,48].

![Figure 3. Progression of organ transplant to graft failure. Elevation of dd-cfDNA can be an early indicator of graft damage, rejection and failure.](image)

The levels of dd-cfDNA are affected by anti-rejection therapy and are dose-dependent. Levels of dd-cfDNA decrease rapidly after anti-rejection therapy [57]. This paves the way for us to create personalized immunosuppressive drugs to prevent graft damage and rejection. Furthermore, this will also help to minimize the risk of other diseases, caused by the suppressed immune system of the body and high dosage of immunosuppressive medicines.

It is reported through 16 studies upon the utility and effectiveness of dd-cfDNA in detecting rejection among kidney, heart, liver and lung transplants that the mean sensi-
Activities and specificities of dd-cfDNA are $79.83 \pm 9.15\%$ and $79.61 \pm 14.86\%$, respectively (see Table 2). These studies detail the efficiency of dd-cfDNA to detect antibody-mediated rejection (ABMR) primarily.

Table 2. Sensitivity and specificity of dd-cfDNA to detect graft rejection and/or damage.

| Name             | Organ(s) | Sample Type | Sensitivity (%) | Specificity (%) | PPV (%) | NPV (%) |
|------------------|----------|-------------|-----------------|-----------------|---------|---------|
| Moiera 2009 [27] | Kidney   | Plasma, Urine | 89              | 85              | 53      | 98      |
| Sigdel 2013 [29] | Kidney   | Urine       | 81              | 75              | -       | -       |
| Schutz 2016 [41] | Liver    | Plasma      | 91.2            | 92.5            | -       | -       |
| Schutz 2017 [3]  | Liver    | Plasma      | 90.3            | 92.9            | -       | -       |
| Bloom 2017 [45]  | Kidney   | Plasma      | 81              | 83              | 44      | 96      |
| Jordan 2018 [47] | Kidney   | Plasma      | 81              | 82              | 81      | 83      |
| Weir 2018 [34]   | Kidney   | Plasma      | 69.6            | 84              | 60.9    | 88.6    |
| Khush 2019 [30]  | Heart    | Plasma      | 80              | 44              | 8.7     | 97.1    |
| Sigdel 2019 [52] | Kidney   | Plasma      | 88.7            | 72.6            | 52      | 95      |
| Oellerich 2019 [53] | Kidney | Plasma      | 73              | 73              | 13      | 98      |
| Sayah 2020 [54]  | Lung     | Plasma      | 73.1            | 52.9            | 34      | 85.5    |
| Levine 2020 [73] | Lung     | Plasma      | 81              | 100             | -       | -       |
| Richmond 2020 [74] | Heart | Plasma      | 75              | 79              | -       | -       |
| Puliyanda 2020 [58] | Lung | Plasma      | 86              | 100             | -       | -       |
| Zhao 2021 [75]   | Liver    | Plasma      | 81.8            | 81.9            | 56.2    | 93.9    |
| Khush 2021 [60]  | Lung     | Plasma      | 55.6            | 75.8            | 43.3    | 83.6    |

PPV: Positive predictive value; NPV: Negative predictive value. Mean sensitivities and specificities for dd-cfDNA to diagnose rejection are $79.83 \pm 9.15\%$ and $79.61 \pm 14.96\%$, respectively.

6. Limitations of dd-cfDNA as a Potential Biomarker

The dd-cfDNA method cannot be applied to transplants between identical twins because of the similar genetic makeup which will make it impossible to differentiate donor and recipient DNA [33]. In the case of dual organ transplant from a single donor, dd-cfDNA can identify graft injury but cannot distinguish the affected organ. Furthermore, this will not be applicable to multi-organ transplant recipients where there is more than one donor involved, as the donor DNA will be variable and the recipient will have cell-free donor DNA from more than one graft. Thus, it will be difficult to assess which graft is subject to injury and at a risk of rejection. If one must monitor and study donor DNA in a patient with multiple organ transplants, then one would have to perform genotyping on the recipient’s and donor’s DNA to assess the status of rejection of the organ [33].

Since dd-cfDNA increases with graft injury, the impact of the BK virus, nephrotic syndrome or urinary tract infection on dd-cfDNA levels in kidney transplant patients is still unknown and requires further research.

Lastly, studies directly comparing different techniques and approaches for identifying and quantifying dd-cfDNA are unavailable. Each new assay should require clinical validation before applicability.

7. Conclusions

An understanding of the methods and techniques used to diagnose rejection and graft damage through dd-cfDNA will allow clinicians to understand its applicability and utility in clinical settings. Several studies have clinically validated the utility of dd-cfDNA in monitoring graft damage and diagnosing rejection.
The dd-cfDNA has the advantage of not being affected by any pathological or bodily functions and interrogates the health of graft directly. It allows for the early detection of rejection episodes which will enable clinicians to quickly intervene with immunosuppressive therapies and prevent graft damage or failure. Since it is a non-invasive method, it can be performed frequently and thus paves the way for personalized immunosuppressive therapies. This will prevent recipients from under- or over-immunosuppression and help in minimizing the side effects of immunosuppressive therapies.

The dd-cfDNA may compliment or replace the post-transplant methods to diagnose graft health and rejection. It can help in avoiding unnecessary biopsies. A graft rejection monitoring technique in the form of dd-cfDNA, also referred to as liquid biopsy, opens a new vista for becoming an upcoming gold standard.

8. Future Prospect of dd-cfDNA

The dd-cfDNA has a highly favorable diagnostic performance for graft rejection or injury. It has shown the evidence towards the detection of graft injury and rejection before it can be diagnosed by the present diagnostic methods. It will guide surgeons and transplant teams so that they have enough time to act and prevent graft injury and, in the worst-case scenario, graft loss. The high negative predictive value can be used to avoid unnecessary biopsies. It will help in reducing the risk and discomfort of biopsy along with reducing the burden of cost on the recipient, dd-cfDNA detects the graft injury by immune attack, which is caused by the activation of the immune system, indicating the insufficiency of immunosuppression medications, therefore indicating its potential to help in monitoring immunosuppression and bringing to light the aspect of individualized dosage. This will further help medical professionals to lower the chance of rejection, infection, and other side effects of immunosuppression. This diagnostic method can provide patients with an option to get diagnosed from a home sample collection. This not only makes the diagnosis convenient for patients but can also be used during the COVID-19 pandemic. Transplant patients are at a high risk of contracting COVID-19, and even dying from the disease due to a compromised immune system [76]. Therefore, home sample collection allows the recipient a safer option for receiving a diagnosis along with tele-consultation. Therefore, serial dd-cfDNA monitoring will lead to the cost-effective personalized management of transplant recipients to reduce graft loss.

Future studies should include large cohorts with different dd-cfDNA diagnostic approaches and techniques along with clinical outcomes, as well as the personalization of immunosuppression. The impact of other diseases and pathophysiology also needs to be investigated.

Author Contributions: N.K., R.R., and A.G. contributed to the acquisition of data, analysis and interpretation of data, and drafted the article; D.S.R. and M.P.S. aided in revising the article and including critically important intellectual content. All authors have read and agreed to the published version of the manuscript.

Funding: N.K. is receiving doctoral fellowship from Indian Council of Social Science Research [RFD/2019-20/GEN/HLTR/177].

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: All articles are available from PubMed and Web of Science.

Conflicts of Interest: The authors declare no conflict of interest.
26. Zhang, J.; Tong, K.L.; Li, P.K.; Chan, A.Y.; Yeung, C.K.; Pang, C.C.; Wong, T.Y.; Lee, K.C.; Lo, Y.D. Presence of donor-and recipient-derived DNA in cell-free urine samples of renal transplantation recipients: Urinary DNA chimerism. *Clin. Chem.* **1999**, *45*, 1741–1746. [CrossRef]

27. García Moreira, V.; Prieto García, B.; Baltar Martín, J.M.; Ortega Suárez, F.; Álvarez, F.V. Cell-free DNA as a noninvasive acute rejection marker in renal transplantation. *Clin. Chem.* **2009**, *55*, 1958–1966. [CrossRef] [PubMed]

28. Macher, H.C.; Suárez-Artacho, G.; Guerrero, J.M.; Gómez-Bravo, M.A.; Álvarez-Gómez, S.; Bernal-Bellido, C.; Domínguez-Pascual, I.; Rubio, A. Monitoring of transplanted liver health by quantification of organ-specific genomic marker in circulating DNA from receptor. *PLoS ONE* **2013**, *9*, e113987. [CrossRef] [PubMed]

29. Sigdel, T.K.; Vitalone, M.J.; Tran, T.Q.; Dai, H.; Hsieh, S.C.; Salvatierra, O.; Sarwal, M.M. A rapid noninvasive assay for the detection of renal transplant injury. *Transplantation* **2013**, *96*, *97*. [CrossRef]

30. Snyder, T.M.; Khush, K.K.; Valantine, H.A.; Quake, S.R. Universal noninvasive detection of solid organ transplant rejection. *Proc. Natl. Acad. Sci. USA* **2011**, *108*, 6229–6234. [CrossRef] [PubMed]

31. Beck, J.; Oellerich, M.; Schütz, E. A Universal Droplet Digital PCR Approach for Monitoring of Graft Health after Transplantation Using a Prescreened SNP Set; Digital PCR; Humana Press: New York, NY, USA, 2018; pp. 335–348.

32. Beck, J.; Bierau, S.; Balzer, S.; Andag, R.; Kanzow, P.; Schmitz, J.; Gaedcke, J.; Moerer, O.; Slotta, J.E.; Walson, P.; et al. Digital droplet PCR for rapid quantification of donor DNA in the circulation of transplant recipients as a potential universal biomarker of graft injury. *Clin. Chem.* **2013**, *59*, 1732–1741. [CrossRef]

33. Grskovic, M.; Hiller, D.J.; Eubank, L.A.; Sninsky, J.J.; Christopherson, C.; Collins, J.P.; Thompson, K.; Song, M.; Wang, Y.S.; Ross, D.; et al. Validation of a clinical-grade assay to measure donor-derived cell-free DNA in solid organ transplant recipients. *J. Mol. Diagn.* **2016**, *18*, 890–902. [CrossRef]

34. Weir, M.; Hiller, D.; Yee, J.; Matas, A. Donor-derived cell-free DNA outperforms serum creatinine changes for identifying kidney transplant rejection. *Am. J. Transplant.* **2018**, *18* (Suppl. 4), S06.

35. Consortium, G.P. A global reference for human genetic variation. *Nature* **2015**, *526*, 68–74. [CrossRef]

36. Grskovic, M.; Hiller, D.J.; Eubank, L.A.; Sninsky, J.J.; Christopherson, C.; Collins, J.P.; Thompson, K.; Song, M.; Wang, Y.S.; Ross, D.; et al. Circulating cell-free DNA enables noninvasive diagnosis of heart transplant rejection. *Sci. Transl. Med.* **2014**, *6*, 241ra77.

37. De Vlaminck, I.; Martin, L.; Kertesz, M.; Patel, K.; Kowarsky, M.; Strehl, C.; Cohen, G.; Luikart, H.; Neff, N.F.; Okamoto, J.; et al. Noninvasive monitoring of infection and rejection after lung transplantation. *Proc. Natl. Acad. Sci. USA* **2015**, *112*, 13336–13341. [CrossRef] [PubMed]

38. Beck, J.; Oellerich, M.; Schulz, U.; Schauerte, V.; Reinhard, L.; Fuchs, U.; Knabbe, C.; Zittermann, A.; Olbricht, C.; Gummert, J.F.; et al. Donor-derived cell-free DNA identifies antibody-mediated rejection in donor specific antibody positive kidney transplant recipients. *Transplantation* **2013**, *88*, 1741–1746. [CrossRef] [PubMed]

39. Jordan, S.C.; Bunnapradist, S.; Bromberg, J.S.; Langone, A.J.; Hiller, D.; Yee, J.P.; Sninsky, J.J.; Woodward, R.N.; Matas, A.J. Circulating cell-free DNA enables noninvasive diagnosis of heart transplant rejection. *J. Appl. Lab. Diagn.* **2015**, *2*, 253–262. [CrossRef]

40. Sharfuddin, A.; et al. Cell-free DNA as a noninvasive acute rejection marker in liver transplantation recipients with rejections using donor-recipient HLA mismatch. *Transplant. Direct.* **2017**, *3*, e113937. [CrossRef]

41. Zou, J.; Duffy, B.; Slade, M.; Young, A.L.; Steward, N.; Hachem, R.; Mohanakumar, T. Rapid detection of donor cell-free DNA in lung transplant recipients with rejections using donor-recipient HLA mismatch. *Hum. Immunol.* **2017**, *78*, 342–349. [CrossRef]

42. Bromberg, J.S.; Brennan, D.C.; Poggio, E.; Bunnapradist, S.; Langone, A.; Sood, P.; Matas, A.J.; Mannon, R.B.; Mehta, S.; Sharfuddin, A.; et al. Biological variation of donor-derived cell-free DNA in renal transplant recipients: Clinical implications. *J. Appl. Lab. Med.* **2017**, *2*, 309–321. [CrossRef]

43. Goh, S.K.; Muralidharan, V.; Christphi, C.; Do, H.; Dobrovic, A. Probe-free digital PCR quantitative methodology to measure donor-specific cell-free DNA after solid-organ transplantation. *Clin. Chem.* **2017**, *63*, 742–750. [CrossRef]

44. Bloom, R.D.; Bromberg, J.S.; Poggio, E.D.; Bunnapradist, S.; Langone, A.J.; Sood, P.; Matas, A.J.; Mehta, S.; Mannon, R.B.; Sharfuddin, A.; et al. Cell-free DNA and active rejection in kidney allografts. *J. Am. Soc. Nephrol.* **2017**, *28*, 2221–2232. [CrossRef]

45. Tanaka, S.; Sugimoto, S.; Kurosaki, T.; Miyoshi, K.; Otani, S.; Suzawa, K.; Hashida, S.; Yamane, M.; Oto, T.; Toyooka, S. Donor-derived cell-free DNA is associated with acute rejection and decreased oxygenation in primary graft dysfunction after living donor-lobar lung transplantation. *Sci. Rep.* **2018**, *8*, 1–9. [CrossRef]

46. Jordan, S.C.; Bunnapradist, S.; Bromberg, J.S.; Langone, A.J.; Hiller, D.; Yee, J.P.; Sninsky, J.J.; Woodward, R.N.; Matas, A.J. Donor-derived cell-free DNA identifies antibody-mediated rejection in donor specific antibody positive kidney transplant recipients. *Transplant. Direct.* **2018**, *4*, e028927. [CrossRef]

47. Gilis, E.M.; Beiraert, C.; Dendooven, A.; Meyesman, P.; Laukens, K.; De Schrijver, J.; Van Laecke, S.; Van Biesen, W.; Emonds, M.P.; De Winter, B.Y.; et al. Plasma donor-derived cell-free DNA kinetics after kidney transplantation using a single tube multiplex PCR assay. *PLoS ONE* **2018**, *13*, e0208207.
58. Puliyanda, D.P.; Swinford, R.; Pizzo, H.; Garrison, J.; De Golovine, A.M.; Jordan, S.C. Donor-derived cell-free DNA (dd-cfDNA) assay in acute renal rejection therapy: A prospective cohort study. *Clin. Transplant.* 2019, 6, e608. [CrossRef] [PubMed]

59. Stites, E.; Kumar, D.; Olaitan, O.; John Swanson, S.; Leca, N.; Weir, M.; Bromberg, J.; Melancon, J.; Agha, I.; Fattah, H.; et al. High levels of dd-cfDNA identify patients with TCMR 1A and borderline allograft rejection at increased risk of graft injury. *Am. J. Transplant.* 2020, 20, 2491–2498. [CrossRef] [PubMed]

60. Khush, K.K.; De Vlaminck, I.; Luikart, H.; Ross, D.J.; Nicolls, M.R. Donor-derived, cell-free DNA levels by next-generation targeted sequencing are increased in allograft rejection after lung transplantation. *EJ Open Res.* 2021, 7, 00462-2020. [CrossRef] [PubMed]

61. Thongprayoon, C.; Vaitla, P.; Craici, I.M.; Thongprayoon, C.; Vaitla, P.; Craici, I.M.; Leeaphorn, N.; Hansrivijit, P.; Salim, S.A.; Bathini, T.; et al. The use of donor-derived cell-free DNA for assessment of allograft rejection and injury status. *J Clin. Med.* 2020, 9, 1480. [CrossRef] [PubMed]

62. Bronkhorst, A.J.; Ungerer, V.; Holdenrieder, S. The emerging role of cell-free DNA as a molecular marker for cancer management. *Biomol. Detect. Quantif.* 2019, 17, 100087. [CrossRef] [PubMed]

63. Diehl, F.; Schmidt, K.; Choti, M.A.; Romans, K.; Goodman, S.; Li, M.; Thornton, K.; Agrawal, N.; Sokoll, L.; Szabo, S.A.; et al. Circulating mutant DNA to assess tumor dynamics. *Nat. Med.* 2008, 14, 985–990. [CrossRef]

64. Alekseeva, L.A.; Mironova, N.L.; Brenner, E.V.; Kurilshikov, A.M.; Patutina, O.A.; Zenkova, M.A. Alteration of the exDNA profile in blood serum of LLC-bearing mice under the decrease of tumour invasion potential by bovine pancreatic DNase I treatment. *PLoS ONE* 2017, 12, e0171988.

65. Yu, S.C.; Lee, S.W.; Jiang, P.; Leung, T.Y.; Chan, K.A.; Chiu, R.W.; Lo, Y.D. High-resolution profiling of fetal DNA clearance from maternal plasma by massively parallel sequencing. *Clin. Chem.* 2013, 59, 1228–1237. [CrossRef] [PubMed]

66. Gounden, V.; Bhatt, H.; Jialal, I. Renal function tests. In *StatPearls*; StatPearls Publishing: Treasure Island, FL, USA, 2018.

67. Wilkinson, A. Protocol transplant biopsies: Are they really needed? *Clin. J. Am. Soc. Nephrol.* 2006, 1, 130–137. [CrossRef]

68. Berl, T. American Society of Nephrology renal research report. *J. Am. Soc. Nephrol.* 2005, 16, 1886–1903.

69. Rush, D.; Arlen, D.; Boucher, A.; Busque, S.; Cockfield, S.M.; Girardin, C.; Knoll, G.; Lachance, J.G.; Landsberg, D.; Shapiro, J.; et al. Lack of benefit of early protocol biopsies in renal transplant patients receiving TAC and MMF: A randomized study. *Am. J. Transplant.* 2007, 7, 2538–2545. [CrossRef] [PubMed]

70. Gadi, V.K.; Nelson, J.L.; Boespflug, N.D.; Guthrie, K.A.; Kuhr, C.S. Soluble donor DNA concentrations in recipient serum correlate with pancreas-kidney rejection. *Clin. Chem.* 2006, 52, 379–382. [CrossRef] [PubMed]

71. Mehta, S.G.; Chang, J.H.; Alhamad, T.; Bromberg, J.S.; Hiller, D.J.; Grskovic, M.; Yee, J.P.; Mannon, R.B. Repeat kidney transplant recipients with active rejection have increased donor-derived cell-free DNA. *Am. J. Transplant.* 2019, 19, 1597. [CrossRef] [PubMed]

72. Gordon, P.M.; Khan, A.; Sajid, U.; Chang, N.; Suresh, V.; Dinnik, L.; Lamont, R.E.; Parboosingh, J.S.; Martin, S.R.; Pon, R.T.; et al. An algorithm measuring donor cell-free DNA in plasma of cellular and solid organ transplant recipients that does not require donor or recipient genotyping. *Front. Cardiovasc. Med.* 2016, 22, 33. [CrossRef] [PubMed]

73. Levine, D.J.; Ross, D.J.; Sako, E. Single Center “Snapshot” Experience With Donor-Derived Cell-Free DNA after Lung Transplantation. *Biomark. Insights* 2020, 15, 1177271920958704. [CrossRef] [PubMed]
74. Richmond, M.E.; Zangwill, S.D.; Kindel, S.J.; Deshpande, S.R.; Schroder, J.N.; Bichell, D.P.; Knecht, K.R.; Mahle, W.T.; Wigger, M.A.; Gaglianello, N.A.; et al. Donor fraction cell-free DNA and rejection in adult and pediatric heart transplantation. *J. Heart Lung Transplant.* 2020, 39, 454–463. [CrossRef]

75. Zhao, D.; Zhou, T.; Luo, Y.; Wu, C.; Xu, D.; Zhong, C.; Cong, W.; Liu, Q.; Zhang, J.; Xia, Q. Preliminary clinical experience applying donor-derived cell-free DNA to discern rejection in pediatric liver transplant recipients. *Sci. Rep.* 2021, 11, 1–9.

76. Rinaldi, M.; Bartoletti, M.; Bussini, L.; Pancaldi, L.; Pascale, R.; Comai, G.; Morelli, M.; Ravaioli, M.; Cescon, M.; Cristini, F.; et al. COVID-19 in solid organ transplant recipients: No difference in survival compared to general population. *Transpl. Infect. Dis.* 2021, 23, 13421. [CrossRef]